Literature DB >> 2602729

[Prevention of bacterial infections using ciprofloxacin in granulocytopenic patients with cancer].

R Snoeck, J Gerain, A Leleux, J Libert, F Meunier.   

Abstract

The optimal approach to reduce bacterial infections in granulocytopenic patients is still controversial. Recently, fluoroquinolones have been developed and real progress has been achieved in the prevention of Gram negative bacilli septicemia. This study reports our experience with ciprofloxacin and shows the excellent tolerance of ciprofloxacin by our patients as well as promising data for the reduction of Gram negative bacilli infection. However, practical modalities to prevent infection caused by Gram positive cocci remain to be defined.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2602729

Source DB:  PubMed          Journal:  Rev Med Brux        ISSN: 0035-3639


  2 in total

Review 1.  Use of the quinolones in the prophylaxis and treatment of granulocytopenic immunocompromised cancer patients.

Authors:  P Van der Auwera; J Gérain
Journal:  Drugs       Date:  1993       Impact factor: 9.546

2.  Prospective randomized evaluation of ciprofloxacin versus piperacillin plus amikacin for empiric antibiotic therapy of febrile granulocytopenic cancer patients with lymphomas and solid tumors. The European Organization for Research on Treatment of Cancer International Antimicrobial Therapy Cooperative Group.

Authors:  F Meunier; S H Zinner; H Gaya; T Calandra; C Viscoli; J Klastersky; M Glauser
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.